Cisztás fibrózis: ki dolgozik rajta

Intézményenként egy kártya. Célpontra vagy országra szűkítheted a listát.

• Minden célpont
• CFTR 29
• GLP-1 2
• G6PD 0
• IL-13 0
• MUC1 0
• NF1 1
• PDE4 0
• STAT3 0
• CTNNB1 0
• DMD 1
• EGFR 0
• ERK 0
• HDAC 0
• HMGB1 0
• HTT 1
• IL-1 0
• IL-17 0
• IL-4 0
• IL-6 0
• mTOR 0
• NLRP3 0
• NRF2 0
• PKD1 0
• PPAR 0
• SGLT2 0
• SMN1 1
• TLR4 0

1128 intézményből 24, a friss publikációk és a nyitott vizsgálatok szerint rendezve. Ez nem minőségi rangsor.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Discovery and evolution of CRISPR-Associated Transposons (CAST) for functional RNA-guided integration (CRAFT)

  Kobenhavns Universitet· Kobenhavn, Dánia· EU contribution 263 393 EUR· until 2029. aug.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-DN

  A doctoral training programme for next-generation LUNG-targeted non-viral GENEtic MEDicines (LUNG-GENEMED)

  Politecnico di Milano· Milano, Olaszország· EU contribution 3 876 613 EUR· until 2030. nov.· 7 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Maternal human milk as a Risk factor to the Early-life Exposome (MATREEX)

  King's College London· London, Egyesült Királyság· EU contribution 345 235 EUR· until 2029. febr.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  In vitro and in situ structural characterization of the biofilm-associated functional amyloids in Pseudomonas aeruginosa bacteria (FAPbulous)

  Deutsches Elektronen-Synchrotron Desy· Hamburg, Németország· EU contribution 202 125 EUR· until 2027. dec.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  CellCourier: programmable drug delivery via combinatorial cell targeting and generative design of tailored binding peptides

  Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Fuer Gesundheit und Umwelt Gmbh· Neuherberg, Németország· EU contribution 150 000 EUR· until 2027. jún.

  The disease is named only in the funder's project summary, not in the title.

5 of 11 running projects, newest first. Listed amounts together: 19,9 M EUR.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Leállított, visszavont és felfüggesztett vizsgálatok, a szponzor által a regiszterben megadott okkal, szó szerint idézve.

• Leállították

  A Study to Test the Safety and Effects of Inhaled GDC-6988 in Participants With Muco-obstructive Disease

  NCT06603246· Genentech, Inc.· Frissítve: 2026. okt. 20.

  “Sponsor's Decision”A regiszter szövege, változtatás nélkül. Forrás

• Felfüggesztve

  A Study to Access Activity and Safety With SAR445399 Compared With Placebo in Participants Aged 18 to 80 Years of Age With Non-Cystic Fibrosis Bronchiectasis

  NCT07547436· Sanofi· Frissítve: 2026. júl. 29.

  “The pause is for strategic business reasons to facilitate internal portfolio review. The pause is not due to any concerns with patient safety, with program benefit/risk, or with trial integrity.”A regiszter szövege, változtatás nélkül. Forrás

• Visszavonták

  Real World Environmental Exposure Study With Healthy and Cystic Fibrosis Subjects

  NCT06339450· Centre Hospitalier Intercommunal Creteil· Frissítve: 2026. jún. 16.

  “Significant difficulties in recruiting participants, particularly in the 'cystic fibrosis' group.The constraints placed on participants, in particular the requirement to walk for ten days (5 days in an urban area and 5 days in a green area)”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  MR Imaging of Lung in the Follow-up Assessment of Cystic Fibrosis

  NCT03357562· University Hospital, Bordeaux· Frissítve: 2026. jún. 9.

  “Target number of inclusion not reached”A regiszter szövege, változtatás nélkül. Forrás

• Visszavonták

  Effects of AD on VI in Patients With CF

  NCT03655249· Cliniques universitaires Saint-Luc- Université Catholique de Louvain· Frissítve: 2026. ápr. 29.

  “No recruitement, no grant to support this study”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  Epidemiology and Clinical Characteristics of Non-Tuberculous Mycobacteria Infections in Cystic Fibrosis Patients.

  NCT03312075· University Hospital, Brest· Frissítve: 2026. márc. 20.

  “The pace of patient enrollment was significantly affected by the COVID-19 pandemic. Since this is an epidemiological study that does not require a specific number of patients to meet the primary objective, the enrollment period was not extended.”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  Diagnosis and Treatment of Patients With Cystic Fibrosis

  NCT00001223· National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)· Frissítve: 2026. febr. 4.

  “PI left NIH”A regiszter szövege, változtatás nélkül. Forrás

• Felfüggesztve

  Genomic Resources for Enhancing Available Therapies (GREAT1.0) Study

  NCT04306939· University of Pittsburgh· Frissítve: 2026. jan. 7.

  “Suspended for analysis and to consider further enrollment.”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  Frequency-time Analysis of Pathological Lung Sounds: Detection and Quantification of Pathological Sounds in Patients With Cystic Fibrosis, Pulmonary Fibrosis or COPD (Chronic Obstructive Pulmonary Disease)

  NCT06399094· Groupe Hospitalier de la Region de Mulhouse et Sud Alsace· Frissítve: 2025. nov. 17.

  “Recruitment issue”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  Validation of Therapeutic Efficacy Targeting the Splicing Variants in Cystic Fibrosis and CFTR Pathologies

  NCT05100823· University Hospital, Montpellier· Frissítve: 2025. szept. 18.

  “Enrolment period completed and sufficient number of enrolments to achieve study objectives”A regiszter szövege, változtatás nélkül. Forrás

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

• Natural History of Bronchiectasis

  NCT00943514· National Heart, Lung, and Blood Institute (NHLBI)· Forrás

• Assessment of CFTR-Modulator Treatment in Cystic Fibrosis Lung Disease Using Novel Structural and Functional MRI

  NCT04391322· The Hospital for Sick Children· Forrás

• A Study of 24 to 52 Weeks Treatment to Evaluate The Efficacy And Safety of Galvokimig in Adult Study Participants With Non-Cystic Fibrosis Bronchiectasis

  NCT07720375· UCB Biopharma SRL· Forrás

• Prospective Healthcare-Associated Links in Transmission of Nontuberculous Mycobacteria

  NCT05686837· University of North Carolina, Chapel Hill· Forrás

• TIDES 2.0: Prevalence and Longitudinal Course of Depression, Anxiety, and Behavior Problems in Children With Cystic Fibrosis Under 12 Years of Age

  NCT07048574· State University of New York at Buffalo· Forrás

• Iron Repletion in Cystic Fibrosis

  NCT07903311· University of Michigan· Forrás

• Type 2 Inflammation in Adults With Cystic Fibrosis

  NCT07892443· University of Virginia· Forrás

• Dose Range Finding, Efficacy, and Safety Study of Nebulized CSL787 in Adults With Non-cystic Fibrosis Bronchiectasis (NCFB)

  NCT07048262· CSL Behring· Forrás

• A Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Non-cystic Fibrosis Bronchiectasis

  NCT06280391· Sanofi· Forrás

• Azithromycin to Modify Bronchiectasis Exacerbation Risk

  NCT07608328· Assiut University· Forrás

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 5
• Organoids 20
• CRISPR-Cas Systems 12
• Gene Expression Profiling 13
• Sequence Analysis, RNA 2
• Whole Genome Sequencing 16
• Exome Sequencing 5
• Proteomics 12
• Metabolomics 9
• Mass Spectrometry 4
• Flow Cytometry 2
• Immunohistochemistry 3
• Positron-Emission Tomography 1
• Magnetic Resonance Imaging 21
• Machine Learning 6
• Deep Learning 3
• Cohort Studies 37
• Genome-Wide Association Study 3

• Developmental dynamics of ovine lung in health and cystic fibrosis at single-cell resolution.

  Funct Integr Genomics, 2026. júl.

• Single-cell profiling of BAL in preschool cystic fibrosis reveals macrophage dysregulation and ivacaftor-modified inflammatory programs in the early life lung.

  Mucosal Immunol, 2026. márc.

• Single-cell RNAseq identifies persistent epithelial and immune dysfunction in PwCF by mitigating inter-individual sampling heterogeneity.

  J Cyst Fibros, 2026. márc.

• The single-cell transcriptional landscape of the pediatric cystic fibrosis lung from minimally invasive respiratory specimens.

  Sci Rep, 2026. febr.

• Single-cell RNA-sequencing co-expression analysis with CFTR and CF modifier genes in lung tissue.

  Sci Rep, 2025. dec.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.